Dr. Hilary Luderer is the Director of Translational and Clinical Research at PEAR Therapeutics. She leads the Clinical Team’s research efforts that support PEAR’s user-centered product development process for early stage programs. Dr. Luderer was a key contributor to Pear’s regulatory submission for reSET®, which received FDA clearance in September 2017 as the first prescription digital therapy to treat substance use disorder. In addition, she is currently leading two SBIR projects funded by the National Institute on Drug Abuse (NIDA) to develop next generation prescription digital therapeutics for opioid use disorder.